Thursday, October 15, 2026

Copper Futures Over 8% Down In The Last 21 Sessions

Copper Futures Over 8% Down In The Last 21 Sessions

(VIANEWS) - Copper (HG) has been up by 8.79% for the last 21 sessions. At 05:52 EST on Thursday, 25 May, Copper (HG) is $3.59.

Volume

Today's last reported volume for Copper is 26907, 99.99% below its average volume of 13306430378.16.

Volatility

Copper's last week, last month's, and last quarter's current intraday variation average was a negative 0.14%, a positive 0.07%, and a positive 0.97%, respectively.

Copper's highest amplitude of average volatility was 0.85% (last week), 1.06% (last month), and 0.97% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Copper's commodity is considered to be overbought (>=80).

Previous days news about Copper (HG)

  • Copper: sluggish demand from China points to lower prices – ING. According to FXStreet on Wednesday, 24 May, "We expect Copper prices to remain volatile as the market will continue to react to any policy change from China. "

News about

  • Crude oil forecast: finding its summer range - 24 May 2023. According to DailyForex on Wednesday, 24 May, "Ultimately, the WTI Crude Oil and Brent markets are navigating a volatile landscape as they attempt to establish summer ranges. "
  • According to FXStreet on Tuesday, 23 May, "At the time of writing, WTI Oil is trading in the lower$72s and Brent Crude Oil in the lower $77s. "

More news about Copper (HG).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com